English

BioNexus Gene Lab Coporation

EDGAR

BGLC Quarterly report (10-Q) · filed 2026-08-14

Annual consolidated revenue for 2025: about USD 7.425M, using the latest reported figures. The previous period, 2024, was about USD 9.511M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

76.2 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 76156 USD Source

Operating margin

-370.81%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -282396 USD Source
Revenue: 76156 USD Source

Operating cash flow

-422 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -570162 USD Source
Operating Cash Flow: -147671 USD Source

Free cash flow

-423 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -570162 USD Source
Operating Cash Flow: -147671 USD Source
Capital Expenditure: 575 USD Source
Capital Expenditure: 325 USD Source

Cash and cash equivalents: 1.23 million USD 2026-06-30 Source
Exact value

1232658 USD
Long-term debt including current maturities: Not available
Shares outstanding: 2.42 million shares 2026-06-30 Source
Exact value

2417314 shares

Reported share-count change

34.55% · 621 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

1796597 shares · 2025-06-30· Source
2417314 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

3.13 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 2543823 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 7424911 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 6941151 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 22842 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 76156 USD · 2026-04-01 – 2026-06-30 Source

Net income

-2.58 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -708991 USD · 2025-07-01 – 2025-09-30 Source
Net income: -2984607 USD · 2025-01-01 – 2025-12-31 Source
Net income: -1948490 USD · 2025-01-01 – 2025-09-30 Source
Net income: -543575 USD · 2026-01-01 – 2026-03-31 Source
Net income: -286451 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-847 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -2799444 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -1561979 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -1838382 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -2799444 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -147671 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -570162 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -147671 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

7.04 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 35994 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 30511 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 36971 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 35994 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 325 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 575 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 325 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-854 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -2799444 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -1561979 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -1838382 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -2799444 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -147671 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -570162 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -147671 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 35994 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 30511 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 36971 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 35994 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 325 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 575 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 325 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-14.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 8 of 11 periods available· newest 2025-12-31
Operating income: 8 of 11 periods available· newest 2025-12-31
Net income: 8 of 11 periods available· newest 2025-12-31
Operating cash flow: 8 of 11 periods available· newest 2025-12-31
Capital expenditure: 8 of 11 periods available· newest 2025-12-31
Total assets: 8 of 11 periods available· newest 2025-12-31
Total liabilities: 8 of 11 periods available· newest 2025-12-31
Current assets: 8 of 11 periods available· newest 2025-12-31
Current liabilities: 8 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 8 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-21.9%

Prior period

USD 9.51 million

2024-01-01 – 2024-12-31
Current period

USD 7.42 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

7424911 − 9510646 = -2085735 USD

9510646 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
7424911 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · BioNexus Gene Lab Coporation · 2025-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Year-over-year change in Revenue: -2085735 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 7424911 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1802998 Filing: 000147793226002218 Input fundies:Revenue: 9510646 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1722674 Filing: 000147793226002218
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 1.39 million

Prior period

−USD 1.6 million

2024-01-01 – 2024-12-31
Current period

−USD 2.98 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-2984607 − -1598342 = -1386265 USD

-1598342 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-2984607 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · BioNexus Gene Lab Coporation · 2025-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Year-over-year change in Net income: -1386265 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -2984607 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1295036 Filing: 000147793226002218 Input fundies:NetIncome: -1598342 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1109377 Filing: 000147793226002218
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 254,878

Prior period

−USD 2.09 million

2024-01-01 – 2024-12-31
Current period

−USD 1.84 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-1838382 − -2093260 = 254878 USD

-2093260 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-1838382 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · BioNexus Gene Lab Coporation · 2025-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Year-over-year change in Operating cash flow: 254878 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -1838382 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1229506 Filing: 000147793226002218 Input fundies:OperatingCashFlow: -2093260 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1230189 Filing: 000147793226002218
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-83.7%

Prior period

USD 226,989

2024-01-01 – 2024-12-31
Current period

USD 36,971

2025-01-01 – 2025-12-31

Exact inputs and evidence

36971 − 226989 = -190018 USD

226989 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
36971 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · BioNexus Gene Lab Coporation · 2025-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Year-over-year change in Capital expenditure: -190018 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 36971 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1237733 Filing: 000147793226002218 Input fundies:CapitalExpenditure: 226989 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1238334 Filing: 000147793226002218
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 7.42 million 100% of revenue
Operating costs Derived USD 10.39 million 140% of revenue
Operating income −USD 2.97 million −40% of revenue
Tax, interest and other Derived USD 19,542 0.3% of revenue
Net income −USD 2.98 million −40% of revenue

Cash

Operating cash flow −USD 1.84 million −25% of revenue
Capital expenditure USD 36,971 0.5% of revenue
Free cash flow Derived −USD 1.88 million −25% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 12%16%72%
2019 Operating loss: operating costs were 317% of revenue.
2020 9.6%89%
2021 92%
2022 Operating loss: operating costs were 103% of revenue.
2023 Operating loss: operating costs were 127% of revenue.
2024 Operating loss: operating costs were 117% of revenue.
2025 Operating loss: operating costs were 140% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	212328	152427 Derived	59901	33447 Derived	26454	Unavailable	Source 2018-01-01 – 2018-12-31: 212328 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 59901 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 26454 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -274080 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: -39621 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	126955	402660 Derived	-275705	-29236 Derived	-246469	-230090 Derived	Source 2019-01-01 – 2019-12-31: 126955 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -275705 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -246469 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -217273 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 12817 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	11390440	10116618 Derived	1273822	179724 Derived	1094098	131059 Derived	Source 2020-01-01 – 2020-12-31: 11390440 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 1273822 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 1094098 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 552680 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 421621 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	13362567	12306740 Derived	1055827	304256 Derived	751571	5999 Derived	Source 2021-01-01 – 2021-12-31: 13362567 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 1055827 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 751571 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 9161 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 3162 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	10928707	11219884 Derived	-291177	64789 Derived	-355966	551822 Derived	Source 2022-01-01 – 2022-12-31: 10928707 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -291177 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -355966 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: 551822 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 0 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	9770806	12364394 Derived	-2593588	35455 Derived	-2629043	-1971610 Derived	Source 2023-01-01 – 2023-12-31: 9770806 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -2593588 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -2629043 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -1822212 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 149398 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	9510646	11084348 Derived	-1573702	24640 Derived	-1598342	-2320249 Derived	Source 2024-01-01 – 2024-12-31: 9510646 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -1573702 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -1598342 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -2093260 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 226989 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	7424911	10389976 Derived	-2965065	19542 Derived	-2984607	-1875353 Derived	Source 2025-01-01 – 2025-12-31: 7424911 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -2965065 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -2984607 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -1838382 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 36971 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 7.4M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	212328	Revenue: 212328 Open source
20192019-12-31	Revenue	126955	Revenue: 126955 Open source
20202020-12-31	Revenue	11390440	Revenue: 11390440 Open source
20212021-12-31	Revenue	13362567	Revenue: 13362567 Open source
20222022-12-31	Revenue	10928707	Revenue: 10928707 Open source
20232023-12-31	Revenue	9770806	Revenue: 9770806 Open source
20242024-12-31	Revenue	9510646	Revenue: 9510646 Open source
20252025-12-31	Revenue	7424911	Revenue: 7424911 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-21.9% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 212328 Open source
20192019-12-31	Year over year	-40.2%	Revenue: 126955 Open source Revenue: 212328 Open source
20202020-12-31	Year over year	8,872%	Revenue: 11390440 Open source Revenue: 126955 Open source
20212021-12-31	Year over year	17.3%	Revenue: 13362567 Open source Revenue: 11390440 Open source
20222022-12-31	Year over year	-18.2%	Revenue: 10928707 Open source Revenue: 13362567 Open source
20232023-12-31	Year over year	-10.6%	Revenue: 9770806 Open source Revenue: 10928707 Open source
20242024-12-31	Year over year	-2.7%	Revenue: 9510646 Open source Revenue: 9770806 Open source
20252025-12-31	Year over year	-21.9%	Revenue: 7424911 Open source Revenue: 9510646 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -39.9% 2025

Net margin -40.2% 2025

Free cash flow margin -25.3% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	28.2%	Operating Income: 59901 Open source Revenue: 212328 Open source
20192019-12-31	Operating margin	-217.2%	Operating Income: -275705 Open source Revenue: 126955 Open source
20202020-12-31	Operating margin	11.2%	Operating Income: 1273822 Open source Revenue: 11390440 Open source
20212021-12-31	Operating margin	7.9%	Operating Income: 1055827 Open source Revenue: 13362567 Open source
20222022-12-31	Operating margin	-2.7%	Operating Income: -291177 Open source Revenue: 10928707 Open source
20232023-12-31	Operating margin	-26.5%	Operating Income: -2593588 Open source Revenue: 9770806 Open source
20242024-12-31	Operating margin	-16.5%	Operating Income: -1573702 Open source Revenue: 9510646 Open source
20252025-12-31	Operating margin	-39.9%	Operating Income: -2965065 Open source Revenue: 7424911 Open source
20182018-12-31	Net margin	12.5%	Net Income: 26454 Open source Revenue: 212328 Open source
20192019-12-31	Net margin	-194.1%	Net Income: -246469 Open source Revenue: 126955 Open source
20202020-12-31	Net margin	9.6%	Net Income: 1094098 Open source Revenue: 11390440 Open source
20212021-12-31	Net margin	5.6%	Net Income: 751571 Open source Revenue: 13362567 Open source
20222022-12-31	Net margin	-3.3%	Net Income: -355966 Open source Revenue: 10928707 Open source
20232023-12-31	Net margin	-26.9%	Net Income: -2629043 Open source Revenue: 9770806 Open source
20242024-12-31	Net margin	-16.8%	Net Income: -1598342 Open source Revenue: 9510646 Open source
20252025-12-31	Net margin	-40.2%	Net Income: -2984607 Open source Revenue: 7424911 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 212328 Open source Operating Cash Flow: -274080 Open source Capital Expenditure: -39621 Open source
20192019-12-31	Free cash flow margin	-181.2%	Revenue: 126955 Open source Operating Cash Flow: -217273 Open source Capital Expenditure: 12817 Open source
20202020-12-31	Free cash flow margin	1.2%	Revenue: 11390440 Open source Operating Cash Flow: 552680 Open source Capital Expenditure: 421621 Open source
20212021-12-31	Free cash flow margin	0%	Revenue: 13362567 Open source Operating Cash Flow: 9161 Open source Capital Expenditure: 3162 Open source
20222022-12-31	Free cash flow margin	5%	Revenue: 10928707 Open source Operating Cash Flow: 551822 Open source Capital Expenditure: 0 Open source
20232023-12-31	Free cash flow margin	-20.2%	Revenue: 9770806 Open source Operating Cash Flow: -1822212 Open source Capital Expenditure: 149398 Open source
20242024-12-31	Free cash flow margin	-24.4%	Revenue: 9510646 Open source Operating Cash Flow: -2093260 Open source Capital Expenditure: 226989 Open source
20252025-12-31	Free cash flow margin	-25.3%	Revenue: 7424911 Open source Operating Cash Flow: -1838382 Open source Capital Expenditure: 36971 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -1.8M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	-274080	Operating Cash Flow: -274080 Open source
20192019-12-31	Operating cash flow	-217273	Operating Cash Flow: -217273 Open source
20202020-12-31	Operating cash flow	552680	Operating Cash Flow: 552680 Open source
20212021-12-31	Operating cash flow	9161	Operating Cash Flow: 9161 Open source
20222022-12-31	Operating cash flow	551822	Operating Cash Flow: 551822 Open source
20232023-12-31	Operating cash flow	-1822212	Operating Cash Flow: -1822212 Open source
20242024-12-31	Operating cash flow	-2093260	Operating Cash Flow: -2093260 Open source
20252025-12-31	Operating cash flow	-1838382	Operating Cash Flow: -1838382 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -1.9M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -274080 Open source Capital Expenditure: -39621 Open source
20192019-12-31	Free cash flow	-230090	Operating Cash Flow: -217273 Open source Capital Expenditure: 12817 Open source
20202020-12-31	Free cash flow	131059	Operating Cash Flow: 552680 Open source Capital Expenditure: 421621 Open source
20212021-12-31	Free cash flow	5999	Operating Cash Flow: 9161 Open source Capital Expenditure: 3162 Open source
20222022-12-31	Free cash flow	551822	Operating Cash Flow: 551822 Open source Capital Expenditure: 0 Open source
20232023-12-31	Free cash flow	-1971610	Operating Cash Flow: -1822212 Open source Capital Expenditure: 149398 Open source
20242024-12-31	Free cash flow	-2320249	Operating Cash Flow: -2093260 Open source Capital Expenditure: 226989 Open source
20252025-12-31	Free cash flow	-1875353	Operating Cash Flow: -1838382 Open source Capital Expenditure: 36971 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

6.9% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Liabilities / assets	7.9%	Total Liabilities: 130313 Open source Total Assets: 1652239 Open source
20192019-12-31	Liabilities / assets	8.8%	Total Liabilities: 108872 Open source Total Assets: 1231236 Open source
20202020-12-31	Liabilities / assets	34.1%	Total Liabilities: 3453139 Open source Total Assets: 10115293 Open source
20212021-12-31	Liabilities / assets	25%	Total Liabilities: 2394611 Open source Total Assets: 9574390 Open source
20222022-12-31	Liabilities / assets	23.7%	Total Liabilities: 2075149 Open source Total Assets: 8740162 Open source
20232023-12-31	Liabilities / assets	15.3%	Total Liabilities: 1741941 Open source Total Assets: 11399793 Open source
20242024-12-31	Liabilities / assets	20.2%	Total Liabilities: 2111044 Open source Total Assets: 10433848 Open source
20252025-12-31	Liabilities / assets	6.9%	Total Liabilities: 637856 Open source Total Assets: 9252784 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

10.46× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Current assets / current liabilities	20.64×	Current Assets: 1298354 Open source Current Liabilities: 62893 Open source
20192019-12-31	Current assets / current liabilities	17.11×	Current Assets: 882571 Open source Current Liabilities: 51574 Open source
20202020-12-31	Current assets / current liabilities	2.37×	Current Assets: 7985494 Open source Current Liabilities: 3373598 Open source
20212021-12-31	Current assets / current liabilities	3.07×	Current Assets: 7149855 Open source Current Liabilities: 2328755 Open source
20222022-12-31	Current assets / current liabilities	3×	Current Assets: 6021826 Open source Current Liabilities: 2004077 Open source
20232023-12-31	Current assets / current liabilities	4.93×	Current Assets: 8046800 Open source Current Liabilities: 1630923 Open source
20242024-12-31	Current assets / current liabilities	3.81×	Current Assets: 7430449 Open source Current Liabilities: 1951303 Open source
20252025-12-31	Current assets / current liabilities	10.46×	Current Assets: 5448738 Open source Current Liabilities: 520957 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	USD 26,454 Exact value Exact value: 26454 USD 2018-01-01 – 2018-12-31: 26454 USD Inspect Net Income Open source Share or cite Citation for Net Income · BioNexus Gene Lab Coporation · 2018-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Net Income: 26454 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 26454 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793220001729/bion-20191231.xml#41224 Filing: 000147793220001729 The citation records this snapshot. The page link may show a newer release later.	−USD 274,080 Exact value Exact value: -274080 USD 2018-01-01 – 2018-12-31: -274080 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioNexus Gene Lab Coporation · 2018-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Operating Cash Flow: -274080 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -274080 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793220001729/bion-20191231.xml#52439 Filing: 000147793220001729 The citation records this snapshot. The page link may show a newer release later.	Unavailable The mapped spending value is negative, so its direction is unclear. Source Inspect Capital Expenditure Open source	Unavailable Capital expenditure has a negative mapped value; spending direction is unclear.
2019 2019-01-01 – 2019-12-31	−USD 246,469 Exact value Exact value: -246469 USD 2019-01-01 – 2019-12-31: -246469 USD Inspect Net Income Open source Share or cite Citation for Net Income · BioNexus Gene Lab Coporation · 2019-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Net Income: -246469 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -246469 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793221001795/bion-20201231.xml#54755 Filing: 000147793221001795 The citation records this snapshot. The page link may show a newer release later.	−USD 217,273 Exact value Exact value: -217273 USD 2019-01-01 – 2019-12-31: -217273 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioNexus Gene Lab Coporation · 2019-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Operating Cash Flow: -217273 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -217273 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793221001795/bion-20201231.xml#69518 Filing: 000147793221001795 The citation records this snapshot. The page link may show a newer release later.	USD 12,817 Exact value Exact value: 12817 USD 2019-01-01 – 2019-12-31: 12817 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioNexus Gene Lab Coporation · 2019-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Capital Expenditure: 12817 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12817 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793221001795/bion-20201231.xml#70745 Filing: 000147793221001795 The citation records this snapshot. The page link may show a newer release later.	−USD 230,090 Calculation and evidence -217273 − 12817 USD Exact free cash flow: -230090 USD 2019-01-01 – 2019-12-31: -217273 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 12817 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioNexus Gene Lab Coporation · 2019-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Free cash flow: -230090 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -217273 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793221001795/bion-20201231.xml#69518 Filing: 000147793221001795 Input fundies:CapitalExpenditure: 12817 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793221001795/bion-20201231.xml#70745 Filing: 000147793221001795 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 1.09 million Exact value Exact value: 1094098 USD 2020-01-01 – 2020-12-31: 1094098 USD Inspect Net Income Open source Share or cite Citation for Net Income · BioNexus Gene Lab Coporation · 2020-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Net Income: 1094098 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 1094098 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793222002089/bion_10k.htm#836978 Filing: 000147793222002089 The citation records this snapshot. The page link may show a newer release later.	USD 552,680 Exact value Exact value: 552680 USD 2020-01-01 – 2020-12-31: 552680 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioNexus Gene Lab Coporation · 2020-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Operating Cash Flow: 552680 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 552680 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793222002089/bion_10k.htm#866605 Filing: 000147793222002089 The citation records this snapshot. The page link may show a newer release later.	USD 421,621 Exact value Exact value: 421621 USD 2020-01-01 – 2020-12-31: 421621 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioNexus Gene Lab Coporation · 2020-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Capital Expenditure: 421621 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 421621 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793222002089/bion_10k.htm#874685 Filing: 000147793222002089 The citation records this snapshot. The page link may show a newer release later.	USD 131,059 Calculation and evidence 552680 − 421621 USD Exact free cash flow: 131059 USD 2020-01-01 – 2020-12-31: 552680 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 421621 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioNexus Gene Lab Coporation · 2020-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Free cash flow: 131059 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 552680 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793222002089/bion_10k.htm#866605 Filing: 000147793222002089 Input fundies:CapitalExpenditure: 421621 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793222002089/bion_10k.htm#874685 Filing: 000147793222002089 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 751,571 Exact value Exact value: 751571 USD 2021-01-01 – 2021-12-31: 751571 USD Inspect Net Income Open source Share or cite Citation for Net Income · BioNexus Gene Lab Coporation · 2021-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Net Income: 751571 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 751571 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793223002002/bion_10k.htm#1372809 Filing: 000147793223002002 The citation records this snapshot. The page link may show a newer release later.	USD 9,161 Exact value Exact value: 9161 USD 2021-01-01 – 2021-12-31: 9161 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioNexus Gene Lab Coporation · 2021-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Operating Cash Flow: 9161 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 9161 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793223002002/bion_10k.htm#969062 Filing: 000147793223002002 The citation records this snapshot. The page link may show a newer release later.	USD 3,162 Exact value Exact value: 3162 USD 2021-01-01 – 2021-12-31: 3162 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioNexus Gene Lab Coporation · 2021-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Capital Expenditure: 3162 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3162 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793223002002/bion_10k.htm#975734 Filing: 000147793223002002 The citation records this snapshot. The page link may show a newer release later.	USD 5,999 Calculation and evidence 9161 − 3162 USD Exact free cash flow: 5999 USD 2021-01-01 – 2021-12-31: 9161 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 3162 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioNexus Gene Lab Coporation · 2021-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Free cash flow: 5999 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 9161 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793223002002/bion_10k.htm#969062 Filing: 000147793223002002 Input fundies:CapitalExpenditure: 3162 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793223002002/bion_10k.htm#975734 Filing: 000147793223002002 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 355,966 Exact value Exact value: -355966 USD 2022-01-01 – 2022-12-31: -355966 USD Inspect Net Income Open source Share or cite Citation for Net Income · BioNexus Gene Lab Coporation · 2022-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Net Income: -355966 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -355966 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793224002151/bion_10k.htm#1556798 Filing: 000147793224002151 The citation records this snapshot. The page link may show a newer release later.	USD 551,822 Exact value Exact value: 551822 USD 2022-01-01 – 2022-12-31: 551822 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioNexus Gene Lab Coporation · 2022-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Operating Cash Flow: 551822 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 551822 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793224002151/bion_10k.htm#1112242 Filing: 000147793224002151 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2022-01-01 – 2022-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioNexus Gene Lab Coporation · 2022-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793224002151/bion_10k.htm#1091249 Filing: 000147793224002151 The citation records this snapshot. The page link may show a newer release later.	USD 551,822 Calculation and evidence 551822 − 0 USD Exact free cash flow: 551822 USD 2022-01-01 – 2022-12-31: 551822 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioNexus Gene Lab Coporation · 2022-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Free cash flow: 551822 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 551822 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793224002151/bion_10k.htm#1112242 Filing: 000147793224002151 Input fundies:CapitalExpenditure: 0 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793224002151/bion_10k.htm#1091249 Filing: 000147793224002151 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 2.63 million Exact value Exact value: -2629043 USD 2023-01-01 – 2023-12-31: -2629043 USD Inspect Net Income Open source Share or cite Citation for Net Income · BioNexus Gene Lab Coporation · 2023-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Net Income: -2629043 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2629043 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793225002725/bglc_10k.htm#1161467 Filing: 000147793225002725 The citation records this snapshot. The page link may show a newer release later.	−USD 1.82 million Exact value Exact value: -1822212 USD 2023-01-01 – 2023-12-31: -1822212 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioNexus Gene Lab Coporation · 2023-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Operating Cash Flow: -1822212 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1822212 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793225002725/bglc_10k.htm#1266658 Filing: 000147793225002725 The citation records this snapshot. The page link may show a newer release later.	USD 149,398 Exact value Exact value: 149398 USD 2023-01-01 – 2023-12-31: 149398 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioNexus Gene Lab Coporation · 2023-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Capital Expenditure: 149398 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 149398 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793225002725/bglc_10k.htm#1274830 Filing: 000147793225002725 The citation records this snapshot. The page link may show a newer release later.	−USD 1.97 million Calculation and evidence -1822212 − 149398 USD Exact free cash flow: -1971610 USD 2023-01-01 – 2023-12-31: -1822212 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 149398 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioNexus Gene Lab Coporation · 2023-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Free cash flow: -1971610 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1822212 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793225002725/bglc_10k.htm#1266658 Filing: 000147793225002725 Input fundies:CapitalExpenditure: 149398 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793225002725/bglc_10k.htm#1274830 Filing: 000147793225002725 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 1.6 million Exact value Exact value: -1598342 USD 2024-01-01 – 2024-12-31: -1598342 USD Inspect Net Income Open source Share or cite Citation for Net Income · BioNexus Gene Lab Coporation · 2024-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Net Income: -1598342 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1598342 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1109377 Filing: 000147793226002218 The citation records this snapshot. The page link may show a newer release later.	−USD 2.09 million Exact value Exact value: -2093260 USD 2024-01-01 – 2024-12-31: -2093260 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioNexus Gene Lab Coporation · 2024-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Operating Cash Flow: -2093260 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -2093260 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1230189 Filing: 000147793226002218 The citation records this snapshot. The page link may show a newer release later.	USD 226,989 Exact value Exact value: 226989 USD 2024-01-01 – 2024-12-31: 226989 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioNexus Gene Lab Coporation · 2024-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Capital Expenditure: 226989 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 226989 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1238334 Filing: 000147793226002218 The citation records this snapshot. The page link may show a newer release later.	−USD 2.32 million Calculation and evidence -2093260 − 226989 USD Exact free cash flow: -2320249 USD 2024-01-01 – 2024-12-31: -2093260 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 226989 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioNexus Gene Lab Coporation · 2024-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Free cash flow: -2320249 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -2093260 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1230189 Filing: 000147793226002218 Input fundies:CapitalExpenditure: 226989 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1238334 Filing: 000147793226002218 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 2.98 million Exact value Exact value: -2984607 USD 2025-01-01 – 2025-12-31: -2984607 USD Inspect Net Income Open source Share or cite Citation for Net Income · BioNexus Gene Lab Coporation · 2025-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Net Income: -2984607 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2984607 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1295036 Filing: 000147793226002218 The citation records this snapshot. The page link may show a newer release later.	−USD 1.84 million Exact value Exact value: -1838382 USD 2025-01-01 – 2025-12-31: -1838382 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BioNexus Gene Lab Coporation · 2025-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Operating Cash Flow: -1838382 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1838382 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1229506 Filing: 000147793226002218 The citation records this snapshot. The page link may show a newer release later.	USD 36,971 Exact value Exact value: 36971 USD 2025-01-01 – 2025-12-31: 36971 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BioNexus Gene Lab Coporation · 2025-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Capital Expenditure: 36971 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 36971 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1237733 Filing: 000147793226002218 The citation records this snapshot. The page link may show a newer release later.	−USD 1.88 million Calculation and evidence -1838382 − 36971 USD Exact free cash flow: -1875353 USD 2025-01-01 – 2025-12-31: -1838382 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 36971 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BioNexus Gene Lab Coporation · 2025-12-31 BioNexus Gene Lab Coporation (edgar:1737523) Free cash flow: -1875353 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 6d1bbb98deab80b40a538703d34d9cc30456096df7432c0abbf374a043a17791 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1737523?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1838382 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1229506 Filing: 000147793226002218 Input fundies:CapitalExpenditure: 36971 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1737523/000147793226002218/bglc_10k.htm#1237733 Filing: 000147793226002218 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

43 filings · 1,866 latest values · 1,866 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001737523, 1737523, BGLC, bion, edgar:1737523

Also known as BIONEXUS GENE LAB CORP, BIONEXUS GENE LAB CORP., BioNexus Gene Lab Coporation, BioNexus Gene Lab Corp, BioNexus Gene Lab Corp.

BioNexus Gene Lab Coporation

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation